Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CF-012
- Development stage
- Preclinical
- Lead developer
- C-Further
- Modality
- Small Molecules
01
Overview
CF-012 is a first-in-class small molecule inhibitor targeting the transcription factor ETV6, currently in preclinical development by C-Further. Developed in collaboration with the UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute, and Mass General Brigham, CF-012 is designed to disrupt the oncogenic function of ETV6, which has been identified as a critical transcriptional dependency for tumor growth and metastasis in Ewing sarcoma. By inhibiting ETV6, the drug aims to address the urgent unmet need for effective treatments in young patients with relapsed or metastatic Ewing sarcoma, a rare and aggressive bone tumor.
02
Targets
ETV6 (ETS variant transcription factor 6)
Beyond the preview
Go deeper on CF-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CF-012.